These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6752035)

  • 1. Limited protective effect of rough mutant antisera in murine Escherichia coli bacteremia.
    Peter G; Chernow M; Keating MH; Ryff JC; Zinner SH
    Infection; 1982; 10(4):228-32. PubMed ID: 6752035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiserum against Escherichia coli J5: a re-evaluation of its in vitro and in vivo activity against heterologous gram-negative bacteria.
    Trautmann M; Hahn H
    Infection; 1985; 13(3):140-5. PubMed ID: 3897069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-reactive immunoprotective antibodies to Escherichia coli O111 rough mutant J5.
    Sakulramrung R; Domingue GJ
    J Infect Dis; 1985 Jun; 151(6):995-1004. PubMed ID: 3889175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endotoxin neutralization with rabbit antisera to Escherichia coli J5 and other gram-negative bacteria.
    Warren HS; Novitsky TJ; Bucklin A; Kania SA; Siber GR
    Infect Immun; 1987 Jul; 55(7):1668-73. PubMed ID: 3298063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective capacity of antibodies to outer-membrane components of Escherichia coli in a systemic mouse peritonitis model.
    Vuopio-Varkila J; Karvonen M; Saxén H
    J Med Microbiol; 1988 Feb; 25(2):77-84. PubMed ID: 2448461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of antisera to J5 and R595 rough mutants to reduce endotoxemic lethality.
    Greisman SE; Johnston CA
    J Infect Dis; 1988 Jan; 157(1):54-64. PubMed ID: 2447200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.
    Bhattacharjee AK; Opal SM; Taylor R; Naso R; Semenuk M; Zollinger WD; Moran EE; Young L; Hammack C; Sadoff JC; Cross AS
    J Infect Dis; 1996 May; 173(5):1157-63. PubMed ID: 8627067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of mucin and hemoglobin in experimental murine gram-negative bacteremia enhances the immunoprotective action of antibodies reactive with the lipopolysaccharide core region.
    Appelmelk BJ; Verwey-van Vught AM; Maaskant JJ; Schouten WF; Thijs LG; Maclaren DM
    Antonie Van Leeuwenhoek; 1986; 52(6):537-42. PubMed ID: 3545072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia.
    Braude AI; Ziegler EJ; Douglas H; McCutchan JA
    J Infect Dis; 1977 Aug; 136 Suppl():S167-73. PubMed ID: 330776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against enteric septicemia of catfish (Ictalurus punctatus) by immunization with the R-mutant, Escherichia coli (J5).
    Tyler JW; Klesius PH
    Am J Vet Res; 1994 Sep; 55(9):1256-60. PubMed ID: 7802393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis.
    Mellata M; Mitchell NM; Schödel F; Curtiss R; Pier GB
    Vaccine; 2016 Jan; 34(5):656-662. PubMed ID: 26707217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to O and rough antigens against endotoxin.
    Johns M; Skehill A; McCabe WR
    J Infect Dis; 1983 Jan; 147(1):57-67. PubMed ID: 6185599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiserum treatment of gram-negative bacteremia.
    Braude AI; Ziegler EJ; McCutchan JA
    Schweiz Med Wochenschr; 1978 Dec; 108(48):1872-6. PubMed ID: 362528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.
    Ziegler EJ; McCutchan JA; Fierer J; Glauser MP; Sadoff JC; Douglas H; Braude AI
    N Engl J Med; 1982 Nov; 307(20):1225-30. PubMed ID: 6752708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reactive antibody in immunity to colisepticemia in calves.
    Wickstrom ML; Gay CC; Hodgson JL; Widders PR; Schaeffer D; Lee R; Corbeil LB
    Vet Microbiol; 1987 Mar; 13(3):259-71. PubMed ID: 3310376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization against nosocomial infection.
    Braude AI; Ziegler EJ; McCutchan JA; Douglas H
    Am J Med; 1981 Feb; 70(2):463-6. PubMed ID: 7008592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic effects of pretreatment with Escherichia coli J5 antiserum on guinea pig gram-negative bacterial sepsis.
    Dunn DL; Mach PA; Dalmasso AP; Ferguson RM; Cerra FB
    J Surg Res; 1985 Mar; 38(3):298-304. PubMed ID: 3884902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of gram-negative bacterial sepsis: enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5.
    Dunn DL; Ferguson RM
    Surgery; 1982 Aug; 92(2):212-9. PubMed ID: 7048594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration in vivo of recombinant interleukin 2 protects mice against septic death.
    Weyand C; Goronzy J; Fathman CG; O'Hanley P
    J Clin Invest; 1987 Jun; 79(6):1756-63. PubMed ID: 3294901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental gram-negative bacterial sepsis: reevaluation of the ability of rough mutant antisera to protect mice.
    Greisman SE; DuBuy JB; Woodward CL
    Proc Soc Exp Biol Med; 1978 Jul; 158(3):482-90. PubMed ID: 356058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.